Adverse Events Seen With JAK Inhibitors for Myelofibrosis

The JAK inhibitors approved for myelofibrosis have common side effects of cytopenias and gastrointestinal issues, with additional risks of weight gain and cardiac effects and diarrhea; momelotinib and pacritinib show improved tolerability compared to earlier JAK inhibitors.

CML Alliance
Enable registration in settings - general
Compare items
  • Total (0)
Shopping cart